Last $0.52 USD
Change Today +0.0097 / 1.90%
Volume 10.0K
TPI On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

tianyin pharmaceutical co in (TPI) Snapshot

Open
$0.50
Previous Close
$0.51
Day High
$0.52
Day Low
$0.50
52 Week High
03/6/14 - $1.37
52 Week Low
10/14/14 - $0.43
Market Cap
15.3M
Average Volume 10 Days
59.9K
EPS TTM
$-0.03
Shares Outstanding
29.4M
EX-Date
05/11/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TIANYIN PHARMACEUTICAL CO IN (TPI)

Related News

No related news articles were found.

tianyin pharmaceutical co in (TPI) Related Businessweek News

No Related Businessweek News Found

tianyin pharmaceutical co in (TPI) Details

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company, develops, manufactures, markets, and sells patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and active pharmaceutical ingredients in the People’s Republic of China. It offers a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company markets its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. Tianyin Pharmaceutical Co., Inc. was founded in 1994 and is headquartered in Chengdu, the People’s Republic of China.

1,000 Employees
Last Reported Date: 12/9/14
Founded in 1994

tianyin pharmaceutical co in (TPI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $100.0K
Chief Financial Officer, Chief Business & Dev...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Advisor of Sal...
Total Annual Compensation: $80.0K
Vice President of Operations
Total Annual Compensation: $80.0K
Vice President of Marketing & Sales
Total Annual Compensation: $80.0K
Compensation as of Fiscal Year 2014.

tianyin pharmaceutical co in (TPI) Key Developments

Tianyin Pharmaceutical Co., Inc. Reports Unaudited Preliminary Consolidated Earnings Results for the First Quarter Ended September 30, 2014

Tianyin Pharmaceutical Co., Inc. reported unaudited preliminary consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, sales were $9,733,381 against $14,748,548 a year ago. Income from operations was $1,420,371 against $2,174,191 a year ago. Income before provision for income tax was $1,332,350 against $2,093,600 a year ago. Net income attributable to the company was $985,825 or $0.03 per basic and diluted share against $1,515,123 or $0.05 per basic and diluted share a year ago. Net cash used in operating activities was $1,118,417 against $245,586 for the same period in the last year. The sales decrease was a result of continuous pricing pressure and restrictive sales policies on generic products compared with the same period last year. The decrease of income from operations was mainly due to the amount of research & development costs towards cardiovascular portfolio centered on GMOL.

Tianyin Pharmaceutical Co., Inc. Announces Consolidated Earnings Results for the Full Year Ended June 30, 2014; Provides Revenue Guidance for the Fiscal 2015

Tianyin Pharmaceutical Co., Inc. announced consolidated earnings results for the full year ended June 30, 2014. Sales for the fiscal year ended June 30, 2014 was $46.6 million, decreased by 31% from $67.5 million for the fiscal year 2013, mainly due to the Hugan incidence, along with generic pricing pressure, sales volume decrease and prolonged JCM production ramp up. Income from operation of $3.0 million compared with $9.3 million in the previous year was mainly the result of decrease of sales and gross margins. Net loss attributable to TPI was $0.8 million or $0.03 basic and diluted earnings per share for the fiscal year ended June 30, 2014, compared with a net income of $6.6 million or $0.23 basic and diluted earnings per share in fiscal year ended June 30, 2013. The loss was mainly caused by the production interruption, sales decrease and related costs that resulted from GMP re-certification. Net cash provided by operating activities was $2,455,283 against $12,949,856 a year ago. Additions to intangible assets – land use right was $6,973,301 against $886,611 a year ago. Revenue of approximately $46.6 million came significantly below previously estimated modest 0%-5% projection year over year mainly due to the production interruption and sales and marketing impact as a result of the Hugan incidence.

Tianyin Pharmaceutical Co., Inc. announced delayed 10-Q filing

On 11/14/2014, Tianyin Pharmaceutical Co., Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:US $0.52 USD +0.0097

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPI.
View Industry Companies
 

Industry Analysis

TPI

Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.4x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIANYIN PHARMACEUTICAL CO IN, please visit www.tianyinpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.